Drug intelligence / Profile preview

amp-1915

Development stage: Phase 1
Lead developer: Baheal Pharma
Modality: Implantable Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
Administration: Oral

Overview

AMP-1915 is a traditional Chinese herbal formula, also known as Huangqisan, developed for the management of metabolic syndrome and diabetes. The formulation consists of extracts from Astragalus, Radix Puerariae (Kudzu root), and Cortex Mori (Mulberry bark). It has been studied in clinical trials as a meal-based intervention—specifically mixed into instant noodles—for patients with metabolic syndrome. The precise mechanism of action remains unknown, but it is rooted in traditional Chinese medicine practices aimed at improving glucose metabolism and relieving symptoms associated with diabetes[1][2].

Other names: Huangqisan

Beyond the preview

Go deeper on amp-1915.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amp-1915.

Explore the full profile